Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Homo sapiens

ABSTRACT: Single-nuncleus RNA sequencing for circulating tumor cell-derived xenograft models of non-metastatic non-small cell lung cancer

PROVIDER: PRJNA755249 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR15403611.fastq.gz	Fastqsanger.gz
	SRR15403612.fastq.gz	Fastqsanger.gz
	SRR15403613.fastq.gz	Fastqsanger.gz
	SRR15403614.fastq.gz	Fastqsanger.gz

Items per page:

1 - 4 of 4

Similar Datasets

Homo sapiens

Project description:Whole genome sequencing of non-metastatic non-small cell lung cancer primary tumor, patient-derived xenografts and Circulating tumor cells derived xenograft

| PRJNA752223 | ENA

a17a9864-115c-41bf-bc8e-97ab5a9737ba - samples

Project description:Data from Representation of genomic intratumor heterogeneity in multi-region non-small cell lung cancer patient-derived xenograft models

| EGAD00001012228 | EGA

Surfactant-assisted one-pot sample preparation for label-free single-cell proteomics

Project description:Large numbers of cells are generally required for quantitative global proteome profiling due to the significant surface adsorption losses associated with sample processing. Such bulk measurement obscures important cell-to-cell variability (cell heterogeneity) and makes proteomic profiling impossible for rare cell populations (e.g., circulating tumor cells (CTCs)). Here we report a surfactant-assisted one-pot sample preparation coupled with mass spectrometry (MS) termed SOP-MS for label-free global single-cell proteomics. SOP-MS capitalizes on the combination of a MS-compatible nonionic surfactant, n-Dodecyl-β-D-maltoside, and hydrophobic surface-based low-bind tubes or multi-well plates for ‘all-in-one’ one-pot sample preparation. This ‘all-in-one’ method including elimination of all sample transfer steps maximally reduces surface adsorption losses for effective processing of single cells, thus significantly improving detection sensitivity for single-cell proteomics. This method allows convenient label-free quantification of hundreds of proteins from single human cells and ~1200 proteins from small tissue sections (close to ~20 cells). When applied to a patient CTC-derived xenograft (PCDX) model at the single-cell resolution, SOP-MS can reveal distinct protein signatures between primary tumor cells and early metastatic lung cells, which are related to the selection pressure of anti-tumor immunity during breast cancer metastasis. The approach paves the way for routine, precise, quantitative single-cell proteomics.

2021-03-11 | PXD022827 | panorama

RNAseq data LUN 156 parental, adagrasib resistant and RMC-4998 resistant LUN156 tumors

Project description:LUN156 is a patient-derived xenograft (PDX) tumor model derived from 73-year-old male Chinese non-small cell lung cancer (NSCLC) patient with a tumor with a KRASG12C mutation.

2025-10-07 | GSE305318 | GEO

Sensitive monitoring of xenograft cancer models using cell-free DNA

Project description:Tumor-derived xenograft mouse models are widely used tools in cancer studies. We reported that in xenograft models without recognizable tumors, however, circulating tumor-derived cell-free DNA (cfDNA) was persistently detectable in peripheral blood long after engraftment, suggesting that measurement of tumor-derived cfDNA could be more sensitive for tumor assessment in xenograft models as well as serve as valuable supplementary parameters in outcome interpretations, especially for those without visible tumors.

2025-04-13 | GSE279360 | GEO

RNAseq analysis of SCLC PDX models

Project description:We investigated the gene expression changes in a library of small cell lung carcinoma (SCLC) patient-derived xenograft (PDX) models.

2022-02-07 | E-MTAB-11230 | biostudies-arrayexpress

Project description:Establishment of Afatinib-Resistant Non-Small Cell Lung Cancer Cells Derived from Tumor Xenograft Model

| PRJNA304376 | ENA

Metastasis-initiating osteosarcoma subpopulations establish paracrine interactions with both lung and tumor cells to create a metastatic niche

Project description:Osteosarcoma is an aggressive and deadly bone tumor, primarily afflicting children, adolescents, and young adults. Poor outcomes for osteosarcoma patients are intricately linked with the development of lung metastasis. While lung metastasis is responsible for nearly all deaths caused by osteosarcoma, identification of biologically defined, metastasis-targeting therapies remains elusive because the underlying cellular and molecular mechanisms that govern metastatic colonization of circulating tumor cells to the lung remains poorly understood. While thousands of tumor cells are released into circulation each day, very few can colonize the lung. Herein, using a combination of a novel organotypic metastasis in vitro model, single-cell RNA sequencing, human xenograft, and murine immunocompetent osteosarcoma models, we find that metastasis is initiated by a subpopulation of hypo-proliferative cells with the unique capacity to sustain production of metastasis promoting cytokines such as IL6 and CXCL8 in response to lung-epithelial derived IL1α. Critically, genomic and pharmacologic disruption of IL1 signaling in osteosarcoma cells significantly reduces metastatic progression. Collectively, our study supports that tumor-stromal interactions are important for metastasis, and suggests that metastatic competency is driven, in part, by the tumor cell’s ability to respond to the metastatic niche. Our findings support that disruption of tumor-stromal signaling is a promising therapeutic approach to disrupt metastasis progression.

2025-08-11 | GSE293148 | GEO

Role of Anlotinib-induced CCL2 decrease in anti-angiogensis and response prediction for Non-Small Cell Lung Cancer therapy

Project description:Purpose: Our previous clinical trials have been demonstrated that Anlotinib can inhibit tumor growth upon refractory advanced non-small cell lung cancer (NSCLC) patients with the possibility mechanism of anti-angiogenesis. The present study sought to reveal the underlying molecular mechanism of Anlotinib-induced anti-angiogenesis in advanced NSCLC. Experimental Design: Computed tomography (CT) was used to evaluate the treatment effect of Anlotinib upon refractory advanced NSCLC patients. Transcriptome profiling was performed to identify the key gene expression alteration in NCI-H1975 cells before and after Anlotinib treatment. NCI-H1975 derived xenograft model was applied to investigate treatment effect and verify anti-angiogenesis mechanism of Anlotinib. Results: Anlotinib induces tumor cytotoxicity on refractory advanced NSCLC patients, NCI-H1975 derived xenograft models and lung adenocarcinoma cell lines. Transcriptome profiling revealed CCL2 blockade could be responsible for Anlotinib-induced anti-angiogenesis. NCI-H1975 derived xenograft model demonstrated Anlotinib-induced CCL2 blockade play an important role in anti-angiogenesis. Conclusions: This study not only offered the first evidence that Anlotinib inhibits angiogenesis via blocking CCL2 expression, but also provided a novel theoretical basis for the application of Anlotinib in advanced NSCLC patients.

2018-11-30 | E-MTAB-5997 | biostudies-arrayexpress

Chemosensitive Relapse in Small Cell Lung Cancer Patient-Derived Xenografts

Project description:<p>Genetic and epigenetic analysis of patient-derived xenograft models of acquired chemoresistance in small cell lung cancer.</p>

| phs001249 | dbGaP

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data